



Mother Nature's Gift of Healing

Restoring Life After Surgery

Non-healing and infected surgical wounds account for
\$13.1 billion in Medicare costs.¹

Faster healing and reduced complications are important considerations to help your patients get back to the life they love after surgery. Advanced therapy treatments may help improve outcomes and help manage cost of care as seen in the use of skin substitutes in lower extremity diabetic foot ulcers.²




Clarix® 100 is a cryopreserved amniotic membrane allograft.

Appropriate for minimally invasive procedures where access and space are anatomically compromised

For a wide array of surgical applications including

- Minimally invasive Achilles
- Midfoot/forefoot fractures
- Tendon/nerve repair
- Ganglion cyst excision
- Bunionectomy
- Cheilectomy



Preserving as Much of Mother Nature as Possible

For over 36 years, our pioneering scientists have focused on understanding the regenerative features of human birth tissue—ultimately identifying HC-HA/PTX3 as a key orchestrator in human birth tissue regenerative healing.³⁻⁷

Our CryoTek® cryopreservation process has been shown to preserve the structural and functional integrity of the HC-HA/PTX3 complex significantly better than heat

dehydration—delivering the benefits of the natural tissue to the wound.⁸

BioTissue® Surgical human birth tissue products are aseptically processed, devascularized and cell devitalized to deliver the innate properties of human birth tissue to the wound environment.

Clarix 100


Cryopreserved amniotic membrane allograft for surgical wound applications, a thinner alternative to Clarix 1K. The allograft is delivered on a non-implantable, gridded paper backing for easier handling and application.

Clarix 100 Cryopreserved Amniotic Membrane Allograft	
Product Code	Size
CR-02-2020	2.0 x 2.0 cm
CR-02-4040	4.0 x 4.0 cm
CR-02-7070	7.0 x 7.0 cm

In 6 weeks

From here...

To here.



Week 1



Week 6

A representative case of hammertoe correction using adjunctive Clarix 100.

At treatment, prior to skin closure for each digit and after copious irrigation with normal saline, a 2.0 x 2.0cm Clarix 100 was cut and applied subcutaneously.

At 6 weeks, the patient reported no pain with full range of motion for all left foot digits.

Case and photos courtesy of Oksana Buttita, DPM PLLC, Hallandale Beach, FL.

The Challenges of Foot & Ankle Surgery

A Surgical Site Infection (SSI) is an infection that occurs after surgery. SSIs can sometimes be superficial involving the skin only, while other times lead to more serious complications such as osteomyelitis.

Patient risk factors for SSI include age, tobacco use, diabetes, and malnutrition and procedure-specific risk factors.

The unique anatomy of the foot and ankle leads to a higher propensity of wound healing complications compared to other orthopedic surgeries due to:⁹

- Thin layer of soft tissue protection of underlying anatomy
- Deficient extremity blood flow around the ankle, especially in patients with comorbidities

SSIs occur in
2% to 4%
of all patients¹⁰⁻¹¹

1. World Union of Wound Healing Societies. Consensus Document. Surgical wound dehiscence: improving prevention and outcomes. *Wound International*, 2018.
2. Armstrong DG, Tettelbach WH, Chang TJ, et al. *J Wound Care*. 2021 Jul 1;30(Sup7):S5-S16. doi: 10.12968/jowc.2021.30.Sup7.S5. PMID: 34256590.
3. Tseng SC. *Invest Ophthalmol Vis Sci*. 2016;57(5):ORSFh1-ORSFh8.
4. He H, Li W, Tseng DY, et al. *J Biol Chem*. 2009;284:20136-46.
5. He H, Zhang S, Tighe S, Son J, Tseng SC. *J Biol Chem*. 2013;288:25792-803.
6. Zhang S, He H, Day AJ, et al. *J Biol Chem*. 2012;287:12433-44.

7. Zhang S, Zhu YT, Chen SY, et al. *J Biol Chem*. 2014;289:13531-42.
8. Cooke M, Tan EK, Mandrycky C, He H, O'Connell J, Tseng SC. *J Wound Care*. 2014;23(10):465-476.
9. Dalton GP, Wapner KL, Hecht PJ. *Clin Orthop Relat Res*. 2001 Oct;(391):133-9.
10. Mu Y, Edwards J, Horan T, Berrios-Torres S, Fridkin S. *Infect Control Hosp Epidemiol*. 2011;32(10):970-986. doi:10.1086/662016.
11. McKibben L, Horan T, Tokars J, et al. *Infect Control Hosp Epidemiol*. 2005;26(6):580-587. doi:10.1086/502585.

www.biotissue.com/surgical

7300 Corporate Drive, Suite 700, Miami, FL 33126 | 888.296.8858

© 2022 BioTissue, Inc. All rights reserved | US-CL-2200002



Clarix, Neox, CryoTek, and BioTissue are registered trademarks of TissueTech, Inc. All other trademarks used herein are proprietary to their respective owners. AmnioX Medical, Inc.'s products are now part of the BioTissue Surgical brand.

BioTissue Surgical products are authorized under the regulations of the U.S. Food and Drug Administration (FDA) governing the manufacture and distribution of Human Tissue Products. They are marketed as structural tissue products for homologous use and are used by physicians as barriers, wound coverings, conduits, and/or cushions in the treatment of their patients.